Clinical Resources
Hologic is pleased to provide reliable clinical information concerning menorrhagia. To read the abstract of the following publications, simply click on the link below.Review Cooper's study demonstrating a 41% amenorrhea rate and 91% success rate with the NovaSure® procedure after one year.
A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia.
Cooper J, Gimpelson R, Laberge P, Galen D, Garza-Leal JG, Scott J, Leyland N, Martyn P, Liu J. J Am Assoc Gynecol Laparosc. 2002 Nov;9(4):418-28.
Compare endometrial ablation devices: NovaSure, ThermaChoice, HydroThermablator and HerOption.
Summary of safety and effectiveness data from FDA: a valuable source of information on the performance of global endometrial ablation devices.
Cooper J, Gimpelson RJ. J Reprod Med. 2004 Apr;49(4):267-73. Review.
View Clark's study comparing NovaSure to ThermaChoice III, demonstrating higher success rates and lower pain levels associated with NovaSure.
Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office: a randomized controlled trial.
Clark TJ, Samuel N, Malick S, Middleton LJ, Daniels J, Gupta JK. Obstet Gynecol. 2011 Jan;117(1):109-18.
View Penninx's study comparing NovaSure to HydroThermablation, demonstrating higher success rates and lower reintervention rates with NovaSure.
Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding: a randomized controlled trial.
Penninx JP, Mol BW, Engels R, van Rumste MM, Kleijn C, Koks CA, Kruitwagen RF, Bongers MY. Obstet Gynecol. 2010 Oct;116(4):819-26.
Learn why radiofrequency ablation is a predictor for optimal treatment outcomes
Prediction of treatment outcomes after global endometrial ablation.
El-Nashar SA, Hopkins MR, Creedon DJ, St Sauver JL, Weaver AL, McGree ME, Cliby WA, Famuyide AO. Obstet Gynecol. 2009 Jan;113(1):97-106. Erratum in: Obstet Gynecol. 2010 Mar;115(3):663.
See Gallinat's 5-year follow up of NovaSure patients, demonstrating an amenorrhea rate of 75% and a success rate of 98%
An impedance-controlled system for endometrial ablation: five-year follow-up of 107 patients.
Gallinat A. J Reprod Med. 2007 Jun;52(6):467-72
Understand why patients feel significantly less pain during and after the NovaSure procedure compared to the ThermaChoice procedure.
Assessment and comparison of intraoperative and postoperative pain associated with NovaSure and ThermaChoice endometrial ablation systems.
Laberge PY, Sabbah R, Fortin C, Gallinat A. J Am Assoc Gynecol Laparosc. 2003 May;10(2):223-32.
See Fulop's 7-year NovaSure follow up results, illustrating a 97% amenorrhea rate and 100% success rate.
NovaSure impedance controlled endometrial ablation: long-term follow-up results.
Fulop T, Rákóczi I, Barna I. J Minim Invasive Gynecol. 2007 Jan-Feb;14(1):85-90.
Compare success rates between NovaSure and ThermaChoice
Five-year follow up of a randomised controlled trial comparing NovaSure and ThermaChoice endometrial ablation.
Kleijn JH, Engels R, Bourdrez P, Mol BW, Bongers MY.
See Sabbah's success when treating women with intracavitary disease up to 3 cm
Use of the NovaSure Impedance Controlled Endometrial Ablation System in patients with intracavitary disease: 12-month follow-up results of a prospective, single-arm clinical study.
Sabbah R, Desaulniers G. J Minim Invasive Gynecol. 2006 Sep-Oct;13(5):467-71.
